Publications en collaboration avec des chercheurs de Centre Léon Bérard (4)

2024

  1. Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis

    European Journal of Cancer, Vol. 202

2023

  1. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer

    Future oncology (London, England), Vol. 19, Núm. 35, pp. 2349-2359

2017

  1. A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

    Breast Cancer Research and Treatment, Vol. 165, Núm. 3, pp. 601-609

2015

  1. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial

    The Lancet Oncology, Vol. 16, Núm. 16, pp. 1700-1710